Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle

Biochemical Pharmacology

Volumn 51, Issue 7, 1996, Pages 879-886

  Sehested, Maxwell ^a   Jensen, Peter Buhl ^b  

^a AMAGER HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

aclarubicin; bisdioxopiperazine; clerocidin; etoposide; ICRF 187; topoisomerase II

Indexed keywords

ACLARUBICIN; BIS(DIOXOPIPERAZINE) DERIVATIVE; CLEROCIDIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; RAZOXANE; TERPENOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CATALYSIS; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA STRAND BREAKAGE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; IMMUNOBLOTTING; LEUKEMIA L 1210; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030007125     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02241-4     Document Type: Article

References (30)

1. Chen AY and Liu LF, DNA topoisomerases - essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191-218, 1994.
2. Wasserman RA and Wang JC, Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II - Implications in resistance to multiple antitumour drugs targeting the enzyme. J Biol Chem 269: 20943-20951, 1994.
3. Pommier Y, Kerrigan D, Schwartz RE, Swack JA and McCurdy A, Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075-3081, 1986.
4. Danks MK, Schmidt CA, Cirtain MC, Suttle DP and Beck WT, Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869, 1988.
5. Jensen PB, Sørensen BS, Sehested M, Demant EJF, Kjeldsen E, Friche E and Hansen HH, Different modes of anthracycline interaction with topoisomerase II: Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45: 2025-2035, 1993.
6. Chen M and Beck WT, Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 53: 5946-5953, 1993.
7. Jensen PB. Sørensen BS, Sehested M, Grue P, Demant EJF and Hansen HH, Targeting the cytotoxicity of topoisomerase II directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 54: 2959-2963, 1994.
8. Leij L de, Postmus PE, Buys CHCM, Elema JD, Ramaekers F, Poppema S, Brouwer M, Veen AY van der, Mesander G and The TH, Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res 45: 6024-6033, 1985.
9. Jensen PB, Roed H, Sehested M, Demant EJF, Vindeløv L, Christensen IJ and Hansen HH, Doxorubicin sensitivity pattern in an panel of small cell lung cancer cell lines: Correlation to etoposide and vincristine, and inverse correlation to carmustine sensitivity. Cancer Chemother Pharmacol 31: 46-52, 1992.
10. Deffie AM, Batra JK and Goldenberg GJ, Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49: 58-62, 1989.
11. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
12. Kohn KW, Ewig RAG, Erickson LC and Zwelling LA, Measurement of strand breaks and cross links by alkaline elution. In: DNA Repair: A Laboratory Manual of Research Procedures (Eds. Friedberg EC and Hanawalt HC), pp. 379-401. Marcel Dekker Inc., New York, 1981.
13. 2 as a DNA fragmenting agent in the alkaline elution interstrand crosslinking and DNA-protein crosslinking assays. Analyt Biochem 168: 88-93, 1988.
14. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M and Blick M, Characterization of an amsacrine-resistant line of human leukemia cells. J Biol Chem 264: 16411-16420, 1989.
15. Sørensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB and Westergaard O, Mode of action of topoisomerase-II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. J Mol Biol 228: 778-786, 1992.
16. Roca J, Ishida R, Berger JM, Andoh T and Wang JC, Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91: 1781-1785, 1994.
17. Sehested M, Jensen PB, Sørensen BS, Holm B, Friche E and Demant EJF, Antagonistic effect of the cardioprotector (+)-1, 2,-bis(3-5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46: 389-393, 1993.
18. Robinson MJ, Osheroff N, Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 30: 1807-1813, 1991.
19. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, Killtnann SA, Jensen MK, Karle H, Laursen B, Nielsen JB, Nissen NI and Thorling K, Aclarubicin plus cytosein arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia - A Danish national phase-III trial. Leukemia 5: 510-516, 1991.
20. Jensen PB, Sørensen BS, Demant EJF, Sehested M, Jensen PS, Vindeløv L and Hansen HH, Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50: 3311-3316, 1990.
21. Rowe T, Kupfer G and Ross W, Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA-cleavage. Biochem Pharmacol 34: 2483-2487, 1985.
22. Pommier Y, Covey J, Kerrigan D, Mattes W, Markovits J and Kohn KW, Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines. Biochem Pharmacol 36: 3477-3486, 1987.
23. Hellmann K and Rhomberg W, Radiotherapeutic enhancement by razoxane. Cancer Treat Rev 18: 225-240, 1991.
24. Ichihashi T, Kiyoi H, Fukutani H, Kubo K, Yamauchi T, Naoe T, Yamada K and Ohno R, Effective treatment of adult T-cell leukemia with a novel oral antitumor agent, MST-16. Oncology 49: 333-335, 1992.
25. Holm B, Sehested M and Jensen PB, ICRF rescue in etoposide (VP-16) treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol, in press.
26. Osheroff N, Role of the divalent cation in topoisomerase II mediated reactions. Biochemistry 26: 6402-6406, 1987.
27. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K and Andoh T, Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51: 4909-4916, 1991.
28. Hasinoff BB, Kuschak TI, Allan WP, Creighton AM and Yalowich JC, ICRF-187 (dexrazoxane) and other bisdioxopiperazines exert their cytotoxicity through the inhibition of DNA topoisomerase II. Proc Amer Assoc Cancer Res 36: 300, 1995.
29. Roca J and Wang JC, DNA transport by a type II DNA topoisomerase: Evidence in favor of a two-gate mechanism. Cell 77: 609-616, 1994.
30. Kawada S-Z, Yamashita Y, Fujii N and Nakano H, Induction of a heat-stable topoisomerase II-DNA cleavable complex by nonintercalative terpenoides, terpentecin and clerocidin. Cancer Res 51: 2922-2925, 1991.